Agios Pharmaceuticals (AGIO) Revenue (2012 - 2026)
Agios Pharmaceuticals' (AGIO) quarterly Revenue came in at $44.7 million in Q2 2026, up 259.25% YoY from $12.5 million in Q2 2025, and up 115.68% on a QoQ basis from $20.7 million in Q1 2026.
Agios Pharmaceuticals (AGIO) Revenue (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals (AGIO) has 14 years of Revenue data on file, last reported at $44.7 million in Q2 2026.
- Quarterly Revenue rose 259.25% year-over-year to $44.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $98.3 million (up 140.58% YoY) and the FY2025 annual result came in at $54.0 million, up 48.03% from the prior year.
- Revenue rose to $44.7 million in Q2 2026, from $20.7 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $44.7 million in Q2 2026 to a low of $832000.0 in Q1 2022.
- A 5-year average of $10.9 million and a median of $8.4 million in 2024 frame the typical range for Revenue.
- Annual changes were most pronounced in 2023 — Revenue jumped 574.16% — and 2025, when it advanced 6.56%.
- Tracing AGIO's Revenue over 5 years: stood at $4.3 million in 2022, then soared by 64.8% to $7.1 million in 2023, then surged by 51.06% to $10.7 million in 2024, then jumped by 86.09% to $20.0 million in 2025, then soared by 124.09% to $44.7 million in 2026.
- The last three Revenue figures came in at $44.7 million (Q2 2026), $20.7 million (Q1 2026), and $20.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Agios Pharmaceuticals | 2.00 Bn | 1.38 Bn | 41.75 Mn | 44.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.75 Mn |
| Mar 31, 2026 | 20.75 Mn |
| Dec 31, 2025 | 19.97 Mn |
| Sep 30, 2025 | 12.88 Mn |
| Jun 30, 2025 | 12.46 Mn |
| Mar 31, 2025 | 8.73 Mn |
| Dec 31, 2024 | 10.73 Mn |
| Sep 30, 2024 | 8.96 Mn |
| Jun 30, 2024 | 8.62 Mn |
| Mar 31, 2024 | 8.19 Mn |
| Dec 31, 2023 | 7.10 Mn |
| Sep 30, 2023 | 7.40 Mn |
| Jun 30, 2023 | 6.71 Mn |
| Mar 31, 2023 | 5.61 Mn |
| Dec 31, 2022 | 4.31 Mn |
| Sep 30, 2022 | 3.52 Mn |
| Jun 30, 2022 | 5.58 Mn |
| Mar 31, 2022 | 832,000.00 |
| Dec 31, 2020 | 44.05 Mn |
| Sep 30, 2020 | 34.71 Mn |